MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ
38.40
-0.45
-1.16%
After Hours: 38.40 0 0.00% 16:20 02/07 EST
OPEN
38.74
PREV CLOSE
38.85
HIGH
38.92
LOW
38.14
VOLUME
423.92K
TURNOVER
--
52 WEEK HIGH
40.28
52 WEEK LOW
25.53
MARKET CAP
2.12B
P/E (TTM)
35.96
1D
5D
1M
3M
1Y
5Y
1D
Supernus: New Approval Holds Promise Of Increased Growth
Seeking Alpha · 1d ago
Top Supernus Executive Offloads Significant Stock Holdings!
TipRanks · 2d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE) and Supernus Pharmaceuticals (SUPN)
TipRanks · 3d ago
FDA Approves ONAPGO Apomorphine Hydrochloride For Parkinson's Disease Treatment
NASDAQ · 3d ago
BUZZ-Supernus rises after FDA approves its drug-device combination for Parkinson's disease
Reuters · 3d ago
Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease
Dow Jones · 3d ago
Supernus stock climbs 5% on FDA approval of Onapgo
Seeking Alpha · 3d ago
Supernus announces FDA approval of ONAPGO
TipRanks · 3d ago
More
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Webull offers Supernus Pharmaceuticals Inc stock information, including NASDAQ: SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.